Interaction Details

Dabrafenib is classified as belonging to the following category: Cytochrome P450 3A4 (Cyp3A4) Inducers

Theoretically, CYP3A4 inducers might increase the risk of adverse effects from the pyrrolizidine alkaloid constituents in comfrey.
CYP3A4 enzymes convert pyrrolizidine alkaloids, constituents of comfrey, to toxic metabolites. Some case reports show that enzyme inducers, such as phenobarbital, seem to enhance the toxicity of comfrey.

Interaction Rating

Moderate

Likelihood of Occurrence

Possible

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

  • Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health Nutr 2000;3:501-8.
  • Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 2003;39:437-46.
  • Wang YP, Yan J, Fu PP, Chou MW. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid. Toxicol Lett 2005;155:411-20.

Comfrey Overview

Comfrey Comfrey (Symphytum officinale) is an herbaceous plant that belongs to the borage family (Boraginaceae). It is native to Europe and Asia and is known for its hairy, green leaves and small, purple, bell-shaped flowers. Comfrey has a long history of use in traditional medicine and contains a number of active compounds, including allantoin, which is believed to have anti-inflammatory and healing properties. It has been traditionally used to treat a variety of ailments, including wounds, fractures, and skin conditions. In addition, comfrey is believed to have astringent and expectorant effects, and has been used to treat respiratory disorders and coughs. It is important to note that comfrey may cause liver damage if taken in large amounts (orally) or over a long period of time and should be used with caution. The FDA has recommended removal of oral comfrey products from the market due to potential for liver toxicity although it is currently still available. It is most often seen in topical forms (e.g., as an ointment).
See More Information Regarding Comfrey

Dabrafenib Overview

  • Dabrafenib is used alone or in combination with trametinib (Mekinist) to treat a certain types of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. It is also used along with trametinib to treat and prevent the return of a certain type of melanoma after surgery to remove it and any affected lymph nodes. Dabrafenib is also used in combination with trametinib to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. It is also used to treat a certain type of thyroid cancer that has spread to nearby tissues or to other parts of the body that has not responded to previous treatment(s). Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

See More Information Regarding Dabrafenib

Comfrey - More Interactions

Comfrey interacts with 409 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown No interactions have been reported or no interaction data is currently available.

Return to the main herbal interaction checker page

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Drug descriptions are provided by MedlinePlus.

Ask A Pharmacist About Your Herbal Questions!

Dr. Brian Staiger, PharmD

In addition to being a clinical pharmacist specializing in pharmacotherapy, Dr. Brian Staiger is a registered herbalist through the American Herbalist Guild. He has combined his passion for pharmacy practice with the study of medical ethnobotany to improve patient care. Feel free to reach out about any of your herbal or medication questions!

Ask A Pharmacist